skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Intravitreal triamcinolone for intraocular inflammation and associated macular edema

Review

(3478) Views  (885) Full article downloads

Authors: Steven M Couch, Sophie J Bakri

Published Date November 2008 Volume 2009:3 Pages 41 - 47
DOI: http://dx.doi.org/10.2147/OPTH.S4477

Steven M Couch, Sophie J Bakri

Mayo Clinic Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA

Abstract: Triamcinolone acetonide (TA) is a corticosteroid that has many uses in the treatment of ocular diseases because of its potent anti-inflammatory and anti-permeability actions. Intraocular inflammation broadly referred to as uveitis can result from several causes, including the immune system and after ophthalmic surgery. One of the most common reasons for vision loss with uveitis is macular edema. TA has been used for many years as an intravitreal injection for the treatment of ocular diseases. Several case control studies have been reported showing the efficacy of TA in the treatment of intraocular inflammation and associated macular edema caused by Behcet’s disease, Vogt-Koyanagi-Harada syndrome, sympathetic ophthalmia and white dot syndromes. It has also been shown efficacious in cases of pars planitis and idiopathic posterior uveitis. Some authors have reported its use in postoperative cystoid macular edema. Many of the studies on the use of TA in controlling intraocular inflammation and concomitant macular edema showed its effect to be transient in many patients requiring reinjection. Complications can arise from intravitreal injection of TA including elevated intraocular pressure and cataract. Rarely, it can be associated with infectious and non-infectious endophthalmitis. TA may be useful as an adjuvant in the treatment of uveitis and its associated macular edema, especially in patients resistant or intolerant to standard treatment.

Keywords: triamcinolone acetonide, Behcet’s disease, sympathetic ophthalmia, Vogt-Koyanagi-Harada syndrome, white dot syndromes, uveitis, cataract surgery, macular edema, endophthalmitis








Readers of this article also read:

Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery
Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma
Intracameral vancomycin following cataract surgery: An eleven-year study
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Bilateral acute retinal necrosis after herpetic meningitis